about
The TRPA1 channel in migraine mechanism and treatmentThe concept of neurogenic inflammationQuality indicators in headache care: an implementation study in six Italian specialist-care centres.The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo.The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system.Interactions between Natural Health Products and Oral Anticoagulants: Spontaneous Reports in the Italian Surveillance System of Natural Health ProductsCataract in chronic cluster headache: two case reports and review of the literature.Representativeness of the "Fiesole Misurata" study database for use in pharmaco-epidemiological investigations on adherence to antihypertensive medications.Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patientsBedside diagnostic laparoscopy to diagnose intraabdominal pathology in the intensive care unitIt's time for new rules on vitamin D food supplementsCGRP receptors in the control of pain and inflammation.Essential competencies in prescribing: A first european cross-sectional study among 895 final-year medical students.Chronic headaches and medication overuse.Anaphylaxis during the first course of high-dose methotrexate: a case report and literature review.Antidromic vasodilatation and the migraine mechanism.β-adrenergic-blocking drugs and melanoma: current state of the art.TRPA1 and other TRP channels in migraine.TRP channels.P010. OnabotulinumtoxinA for treatment of chronic migraine: results after 1 year of treatment.CGRP receptors and TRP channels in migraine.P057. Prophylaxis with low-dose methadone in patients affected by daily refractory headache and medication-overuse headache: a prospective cohort study (METACEF study).What is the evidence for the role of TRP channels in inflammatory and immune cells?β-Blocker use and reduced disease progression in patients with thick melanoma: 8 years of follow-up.Ureteral relaxation through calcitonin gene-related peptide release from sensory nerve terminals by hypotonic solution.The TRPA1 channel mediates the analgesic action of dipyrone and pyrazolone derivatives.Triptans and CGRP blockade - impact on the cranial vasculature.Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel.Anything to declare? Possible risks for patients' health resulting from undeclared plants in herbal supplements.Dapoxetine treatment in patients with lifelong premature ejaculation: the reasons of a "Waterloo".Migraine relief by chilis and other alternative medications: evidence indicates a central role for trp channels.Pleasant natural scent with unpleasant effects: cluster headache-like attacks triggered by Umbellularia californica.Ethanol causes neurogenic vasodilation by TRPV1 activation and CGRP release in the trigeminovascular system of the guinea pig.Vasodilator activity of hydrogen sulfide (H2S) in human mesenteric arteries.TRPA1 mediates trigeminal neuropathic pain in mice downstream of monocytes/macrophages and oxidative stress.Early tracheostomy in intensive care unit: a retrospective study of 506 cases of video-guided Ciaglia Blue Rhino tracheostomies.Effect of β-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death.The peptide Phα1β, from spider venom, acts as a TRPA1 channel antagonist with antinociceptive effects in mice.TRPA1 Mediates Aromatase Inhibitor-Evoked Pain by the Aromatase Substrate Androstenedione.Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis.
P50
Q27016641-375D8380-7392-40C5-A515-27D857C98B25Q28270661-4A5DCE42-695B-437C-A494-6B5A0A600A29Q33644239-B0250F8D-2A0F-42D4-81A3-A6F1D70CF57BQ33755643-46086CC5-76B8-41BF-85D3-732F014F7A48Q34228530-06455F0C-6716-47D2-B53B-E63637EE8B2DQ34512871-620DF45D-EDD9-4DD7-A265-D31425CCF292Q34595833-5D4D098C-C689-4181-A006-F7B283228A03Q34777786-C4EEDB35-EC01-4AC2-8A22-ECF0975A984AQ35205415-C00E6E2F-B308-4338-BC64-998C03586CD8Q37206788-7555E0DB-DFBC-44EE-A249-377D31E8F55BQ37369354-2AF2B1DD-799E-4314-A0A6-03C68F7C9598Q37373944-5E6D809D-4B5C-40B5-AE7F-C07B3CAD9EB7Q37602796-862AD8A8-2EE0-412A-94A4-C2658F2813A6Q37791925-A0612426-6F18-42C7-83E2-8B802D40E534Q37875202-81076A5F-FE35-4BC2-B9DE-BCFCE1DC82A5Q37971447-FC1B505F-B8BE-4C73-99CF-BE85CB153F2AQ38068208-E2207336-D9CA-4739-9385-05E4779E0762Q38128581-7DDF941B-0C5B-4743-B055-95EAAE3E4973Q38366024-8813CAFE-EC6B-4BC7-BEE4-C0D225D0BAEFQ38550853-5AB4F01A-3315-4694-B994-860C69086426Q38551012-744212D7-2D19-41D9-9B5E-F260ACE3F2EDQ38554231-443FA84C-8964-4C8E-AA36-B4766D25D4A4Q38646773-C5DE85CE-68BA-492F-8DF0-3286A5FEC0E8Q38874054-EF88AC41-1E5B-4F10-87B8-732F4927A333Q38992257-65377A21-A5CB-407B-B1FD-11EE4DDB02E2Q41374415-4AB3A7F0-680E-4644-9AF9-E6AD72BAA518Q42706186-6B7F5228-4859-4407-8BF7-986266C840C9Q42860383-D0605BDB-88B9-4B9E-B387-B29C5040814DQ43193575-2CA6A470-48A2-4F2F-AEA0-CCD00660DFEDQ44844480-230C34D8-738D-4CB8-9501-50DA097FCC08Q45732621-79223BB1-3734-4204-8795-6C14883D5184Q46449977-A2C3652B-1A79-4A49-9513-585379731BEAQ46987679-DCB8B023-D62B-419D-B996-96147545EAFDQ47368313-318BAC2E-356B-4C35-8963-A75BF98DB0B5Q48828544-519B4500-2BBF-4362-B374-EBCB1B8A7542Q50447505-DD409F79-52BE-49AA-8790-CB68CDE9F6F0Q50758365-34FAFCE9-E3DA-4792-8C9E-3AD3453E45A3Q51375560-FAE98759-63DC-4F18-B024-7254D64B8838Q51376178-D477B83B-5EEA-4F14-871A-E79FE1157F10Q53675601-9641C330-C53E-4CF3-93D0-F5D0FC5AE92F
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Silvia Benemei
@ast
Silvia Benemei
@en
Silvia Benemei
@es
Silvia Benemei
@nl
Silvia Benemei
@sl
type
label
Silvia Benemei
@ast
Silvia Benemei
@en
Silvia Benemei
@es
Silvia Benemei
@nl
Silvia Benemei
@sl
prefLabel
Silvia Benemei
@ast
Silvia Benemei
@en
Silvia Benemei
@es
Silvia Benemei
@nl
Silvia Benemei
@sl
P1053
K-5552-2014
P106
P1153
24597388900
P21
P31
P3829
P496
0000-0001-6316-430X